CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02841748
NCT02841748Phase 2Completed
CompareCT.gov

A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.

University of Chicago·interventional·Posted Jul 22, 2016·Updated May 13, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab and Placebo for Head and Neck Cancer and Squamous Cell Carcinoma of the Head and Neck. Completed, enrolled 100 participants across 4 sites.

Detailed Summary

A placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 22, 2016
Enrollment StartMay 10, 2017
Primary CompletionFeb 11, 2025
Study CompletionOct 23, 2025
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 9.9 years ago

Interventions

Pembrolizumabdrug

200mg, every three weeks, iv, x 1 year

Placebodrug

iv, every three weeks, x 1 year